Pfizer 1Q Revenues: $12.9 billion (+1%) 1Q Earnings: $3.6 billion (+14%) Comments: Innovative Health sales were $7.8 billion in the quarter, up 6% driven by continued growth from key brands including Ibrance, Eliquis and Xeljanz. Global operational revenue growth for Ibrance, Eliquis and Xeljanz was 35%, 30% and 29%, respectively. This growth was partially offset by the loss of exclusivity of Viagra in the U.S. Also, in the U.S., Prevnar 13 revenues were down 12%, primarily due to lower gover...